DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,510 shares of the medical device company’s stock after selling 699 shares during the period. Kayne Anderson Rudnick Investment Management LLC’s holdings in DexCom were worth $3,686,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Crewe Advisors LLC purchased a new position in shares of DexCom during the 1st quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom during the second quarter valued at $25,000. DSM Capital Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $28,000. Riverview Trust Co purchased a new stake in shares of DexCom during the first quarter worth about $32,000. Finally, Sachetta LLC raised its position in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,483 shares of company stock worth $201,708. 0.30% of the stock is currently owned by insiders.

DexCom Stock Down 2.1 %

Shares of NASDAQ:DXCM opened at $70.43 on Monday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm’s 50 day moving average price is $78.19 and its 200 day moving average price is $109.37. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock has a market cap of $28.01 billion, a price-to-earnings ratio of 45.44, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the firm posted $0.34 earnings per share. The company’s revenue was up 15.3% compared to the same quarter last year. As a group, equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Barclays decreased their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Finally, Morgan Stanley dropped their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.